Formulations for staphylococcus aureus vaccine

NZ834888AUndetermined Publication Date: 2025-07-17LIMMATECH BIOLOGICS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ834888
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-12
Filing Date
2025-01-10
Publication Date
2025-07-17

AI Technical Summary

Technical Problem

Liquid formulations of Staphylococcus aureus vaccines are not compatible with the lack of cold chain storage infrastructure in low-to-middle income countries, necessitating the development of stable vaccine formulations that can withstand varying temperatures and maintain immunogenicity.

Method used

Development of lyophilized and spray freeze-dried formulations of Staphylococcus aureus vaccine comprising multicomponent vaccines with specific components and stabilizers like sucrose and polysorbate 80, which maintain long-term stability and immunogenicity even at varying temperatures.

Benefits of technology

The formulations exhibit reduced protein aggregation and degradation, retaining at least 70-95% of initial immunogenic activity after storage at various temperatures for up to 24 months, effectively providing protection against Staphylococcus aureus infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1_ABST
    Figure 1_ABST
Patent Text Reader

Abstract

A lyophilized pharmaceutical composition for Staphylococcus Aureus vaccine and the method of generating the lyophilized pharmaceutical composition are provided. Also provided is a spray-freezed dried pharmaceutical composition for Staphylococcus Aureus vaccine and the method of generating the spray-freezed dried pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art